1. Clinical Research Center (CRC), Medical Pathology Center (MPC), Cancer Early Detection and Treatment Center (CEDTC) and Translational Medicine Research Center (TMRC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China
2. Chongqing Technical Innovation Center for Quality Evaluation and Identification of Authentic Medicinal Herbs, Chongqing, China
3. School of Medicine, Chongqing University, Chongqing, China
4. Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, ChinaTumor immune regulation mechanism; Synergistic mechanism of tumor epigenetics and immunity
Chief Physician, Professor and Doctoral Supervisor of Three Gorges Hospital, Chongqing University
Director of the Medical Pathology Center, Clinical Research Center, Early Diagnosis and Treatment Center for Tumors and Translational Medicine Research Center
Director of the Middle Line (NUT) Cancer Specialty
Clinical Focus: Early diagnosis and standardized treatment of tumors, including the establishment of the first national NUT midline carcinoma specialty and the creation of an integrated diagnosis and treatment platform for this disease. Research Focus: Anti-tumor clinical drug development and translational research; research on tumor immune regulation mechanisms; research on the synergistic mechanism of tumor epigenetics and immunity. Currently Responsible Projects: Obtained 5 clinical approval documents for national 1.1 class new drugs; led the formulation of 1 national expert consensus and participated in the formulation of 1 consensus; won the first prize of the China Industry-University-Research Cooperation Innovation Award (individual), the first prize of the China Invention Association's Entrepreneurship and Innovation Award (1/6), the first prize of the Ministry of Education's Scientific and Technological Progress Award (6/16), and the second prize of the provincial and ministerial scientific and technological progress award (6/8); applied for over 20 national invention patents and software copyrights, with 5 authorized; published over 110 SCI papers, including over 50 as first or corresponding author; research results published in Nature, Advanced Science, Science Translational Medicine, JCI, J Hepatol, Circulation Research, Nature Communication, etc.; led 1 sub-project of the National Key Research and Development Program and 2 National Natural Science Foundation of China general projects. Main Academic Appointments: President of the Digital Healthcare Committee of the China Food and Drug Safety Enterprise Quality Promotion Association (FDSA), Vice Chairman of the Integrated Lung Cancer Prevention and Screening Committee of the China Anti-Cancer Association, Chairman of the NUT Midline Carcinoma Gene Diagnosis Working Group of the Gene Diagnosis Committee of the China Anti-Cancer Association, Vice President of the Overseas Chinese Association of Science and Technology and the Liaison Officer of Chongqing.
University of Iowa, Iowa City, USAFocusing on the molecular biology, targeted therapy and tumor immune microenvironment in gynecological cancers. Aims to uncover the molecular mechanisms of gynecological tumors, develop new targeted therapies, and explore the role of immune evasion and ferroptosis in cancer.